PGT-A in Screening of Embryos in the Treatment of Unexplained Recurrent Miscarriage
Preimplantation Genetic Testing for Aneuploidy in Screening of Embryos in the Treatment of Unexplained Recurrent Miscarriage: a Single-center, Prospective Clinical Analysis Based on aCGH Technology
1 other identifier
observational
69
1 country
1
Brief Summary
uRM patients selected PGT-A from 2012 to 2016 were included in this study. Their clinical outcomes were prospectively observed and analyzed to explore the factor influenced the outcomes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2020
CompletedFirst Submitted
Initial submission to the registry
November 3, 2020
CompletedFirst Posted
Study publicly available on registry
November 25, 2020
CompletedNovember 25, 2020
November 1, 2020
Same day
November 3, 2020
November 20, 2020
Conditions
Outcome Measures
Primary Outcomes (8)
Baseline characteristics
Age
January 2012 to December 2016
Baseline characteristics
basal sex hormone
January 2012 to December 2016
Baseline characteristics
the number of abortion
January 2012 to December 2016
laboratory outcomes of patients
Oocyte count
January 2012 to December 2016
laboratory outcomes of patients
Number of blastocysts
January 2012 to December 2016
clinical outcoms
normal karyotype blastocyst rate
January 2012 to January 2020
clinical outcoms
live birth rate
January 2012 to January 2020
clinical outcoms
Cumulative pregnancy rate
January 2012 to January 2020
Study Arms (3)
Two spontaneous abortions
No intervention
three spontaneous abortions
No intervention
Four or more spontaneous abortions
No intervention
Eligibility Criteria
women with uRM who underwent array-comparative genomic hybridization (array-CGH) for PGT-A in the Reproductive Medicine Center of Peking University Third Hospital from 2012 to 2016
You may qualify if:
- women with uRM who underwent array-comparative genomic hybridization (array-CGH) for PGT-A in the Reproductive Medicine Center of Peking University Third Hospital from 2012 to 2016.Only the first cycle was included. All patients underwent adequate clinical and genetic consultations before undergoing PGT-A, and all voluntarily chose PGT-A after fully understanding its risks and benefits. All patients signed the informed consent document of PGT-A.
You may not qualify if:
- Couples with parental chromosomal abnormalities were excluded, as were women with anatomical abnormalities of the uterus, autoimmune diseases, and endocrine abnormalities.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Center of Reproductive Medicine, Peking University Third Hospital
Beijing, Haidian, 100191, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Haiyan Wang, M.D.
Center of Reproductive Medicine, Peking University Third Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
November 3, 2020
First Posted
November 25, 2020
Study Start
January 1, 2020
Primary Completion
January 1, 2020
Study Completion
February 1, 2020
Last Updated
November 25, 2020
Record last verified: 2020-11
Data Sharing
- IPD Sharing
- Will not share